Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Comparison Of Clinical Manifestations Between Patients With Ocular Myasthenia Gravis And Generalized Myasthenia Gravis

H. Roh, S. Y. Lee, J. Yoon
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Purpose To compare the clinical manifestations between patients with ocular myasthenia gravis and those with generalized myasthenia gravis (MG). Methods The medical records of 71 patients diagnosed with MG between January 1995 and December 2007 were reviewed. Demographics, sensitivities of diagnostic methods, the presence of systemic autoimmune diseases, ophthalmic complications caused by MG, and treatments were evaluated and compared. Results Fourteen patients (20%) were diagnosed with ocular MG and 57 patients (80%) with generalized MG. Sensitivities of anti-acetylcholine receptor antibody and repetitive nerve stimulation tests were significantly higher in the generalized MG group (84%, 89%) compared to those in the ocular MG group (50%, 54%) (p = 0.011, p = 0.008). The sensitivity of the neostigmine test was the highest in both groups (98% of generalized MG, 79% of ocular MG), and the difference between the two groups was borderline significant (p = 0.058). The most common symptoms were ptosis and diplopia, and both groups presented with pain, blurred vision, and tearing. Systemic autoimmune disease was more prominent in the generalized MG group (21%) than in the ocular MG group (14%), and steroid therapy was used more frequently in the generalized MG group (82%) than in the ocular MG group (57%). Ophthalmic complications associated with long-term steroid treatment were more profound in the generalized MG (30%) compared to those of the ocular MG (21%). Conclusions The generalized MG group was associated with higher sensitivities to diagnostic tests, more systemic steroid use, higher ophthalmic complications caused by systemic autoimmune disease, and long-term steroid treatment compared to those of the ocular MG group.
This paper references
Myasthenia gravis: past, present, and future.
B. Conti-Fine (2006)
The Course of Myasthenia Gravis and Therapies Affecting Outcome a
D. Grob (1987)
Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis
Jared J Mee (2003)
Medical treatment options for ocular myasthenia gravis
A. Antonio‐Santos (2008)
Myasthenia gravis: pathogenesis and treatment.
D. Richman (1994)
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
M. Kupersmith (2003)
Beneficial effects of corticosteroids on ocular myasthenia gravis.
M. Kupersmith (1996)
Treatment strategies for myasthenia gravis Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis
J Díaz-Manera (2007)
Treatment strategies for myasthenia gravis
J. Díaz-Manera (2009)
An ice test for the diagnosis of myasthenia gravis.
K. Golnik (1999)
Why are eye muscles frequently involved in myasthenia gravis?
H. Kaminski (1990)
What causes steroid cataracts? A review of steroid‐induced posterior subcapsular cataracts
A. Jobling (2002)
Thymectomy in the treatment of ocular myasthenia gravis.
P. Roberts (2001)
Associated autoimmune diseases in myasthenia gravis A population‐based study
P. Christensen (1995)
Corticosteroids and Glaucoma Risk
R. C. Tripathi (1999)
Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment
M. Kupersmith (2005)
Corticosteroids and central serous chorioretinopathy.
C. Carvalho-Recchia (2002)
Ocular and Generalized Myasthenia Gravis 7 myasthenia gravis and therapies affecting outcome
NP Robertson (1987)
Prognosis of ocular myasthenia
C. Bever (1983)
Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England
N. Robertson (1998)
Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
N. Sommer (1997)
Ocular Myasthenia Gravis and Graves Disease in a 10-year-old Child
I. Koves (2009)
Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?
M. Kupersmith (2004)
The relationship of age to outcome in myasthenia gravis
D. Donaldson (1990)
Treatment of ocular myasthenia with corticosteroids: yes.
M. Agius (2000)
The effect of prednisone on the progression from ocular to generalized myasthenia gravis
N. Monsul (2004)
A systematic review of diagnostic studies in myasthenia gravis
M. Benatar (2006)
The Usefulness of Ice Test for Diagnosis of Myasthenia Gravis in Patients with Ptosis
Sang-Jun Hwang (2005)
Diagnostic sensitivity of the laboratory tests in myasthenia gravis
S. Oh (1992)
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
R. Beekman (1997)
Long-term outcome and quality of life after thymectomy for myasthenia gravis.
C. Busch (1996)
The course of HS Roh, et al. Ocular and Generalized Myasthenia Gravis 7 myasthenia gravis and therapies affecting outcome
D Grob (1987)
A systematic review of population based epidemiological studies in Myasthenia Gravis
A. Carr (2010)
Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
N. Chirapapaisan (2007)
Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects
N Sommer (1993)
Ocular myasthenia gravis in a senior population: Diagnosis, therapy, and prognosis
J. A. Allen (2010)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar